← Evidence library

BIB_336

Leachman SA, Ascierto PA, Khattak A, et al. (Oregon Health & Science University + KEYNOTE-716 investigators). KEYNOTE-716 long-term update: nonmelanoma skin cancer incidence and new primary melanoma during adjuvant pembrolizumab vs placebo in resected Stage IIB/IIC cutaneous melanoma. JAMA Network Open February 2026. 976 patients; median follow-up 52.8 months. Key counter-intuitive finding: pembrolizumab arm had LOWER NMSC incidence (BCC 3.9% vs 5.3% placebo; SCC 1.8% vs 3.5% placebo). New invasive primary melanoma similar (2.5% pembro vs 1.8% placebo). Severe immune-mediated skin reactions 3.…

Evidence grade

A

Tier

1 (JAMA Netw Open + phase III LT update)

Cited by tasks

05a, 17, 19b

Identifiers

—

Full extracted findings & patient-implication analysis: bibliography/BIB_336/findings.md (research corpus). This page is a short context summary — not individualised medical advice.